Last reviewed · How we verify
AIR DNase
AIR DNase is a recombinant human deoxyribonuclease that degrades extracellular DNA to reduce mucus viscosity and improve airway clearance in cystic fibrosis.
AIR DNase is a recombinant human deoxyribonuclease that degrades extracellular DNA to reduce mucus viscosity and improve airway clearance in cystic fibrosis. Used for Cystic fibrosis.
At a glance
| Generic name | AIR DNase |
|---|---|
| Sponsor | Protalix |
| Drug class | Recombinant enzyme |
| Target | Extracellular DNA |
| Modality | Small molecule |
| Therapeutic area | Respiratory / Pulmonary |
| Phase | Phase 2 |
Mechanism of action
The drug breaks down DNA present in sputum and mucus secretions, which contributes to the thick, sticky consistency that obstructs airways in cystic fibrosis patients. By enzymatically degrading this extracellular DNA, AIR DNase reduces mucus viscosity and improves mucociliary clearance, potentially enhancing lung function and reducing respiratory infections.
Approved indications
- Cystic fibrosis
Common side effects
- Respiratory tract irritation
- Cough
- Hemoptysis
Key clinical trials
- Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of AIR DNase™in Patients With Cystic Fibrosis Previously Treated With Pulmozyme® (PHASE2)
- Safety, Tolerability and Pharmacokinetics Study of AIR DNAse Administered by Inhalation to Healthy Adult Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |